EP Patent

EP3372229A1 — Methods of increasing tonic inhibition and treating secondary insomnia

Assigned to Ovid Therapeutics Inc · Expires 2018-09-12 · 8y expired

What this patent protects

The invention relates to a pharmaceutical composition comprising an effective amount of 4,5,6,7- tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier or excipient for use in a method of treating a hum…

USPTO Abstract

The invention relates to a pharmaceutical composition comprising an effective amount of 4,5,6,7- tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a pharmaceutically effective salt thereof and a pharmaceutically acceptable carrier or excipient for use in a method of treating a human subject with Angelman syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP3372229A1
Jurisdiction
EP
Classification
—
Expires
2018-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Ovid Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.